Apyx Medical Q2 revenue falls 10% to $12.1M; net loss widens; updates FY2024 guidance

Apyx Medical Corp

2024-Q2 EPS reported -$0.41 revenue$22,393,000

Revenue $12.1M (-10% YoY); Advanced Energy -17% to $9.8M, OEM +29% to $2.4M.
Net loss $6.6M ($0.19/share) vs $1.0M loss in Q2 2023; prior year had $2.7M sale-leaseback gain.
Adjusted EBITDA loss $4.3M, up 166% from $1.6M loss in Q2 2023.
FY2024 revenue guidance narrowed to $50.6-52.1M (from $49.7-52.9M); net loss guided $23.5-24.5M (improved).
Stavros Vizirgianakis appointed Chairman effective May 7, 2024, succeeding retiring Andrew Makrides.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.